Although the formalin test is a widely used model of persistent pain, the primary afferent fiber types that underlie the cellular and behavioral responses to formalin injection are largely unknown. Here we used a combined genetic and pharmacological approach to investigate the effect of ablating subsets of primary afferent nociceptors on formalin-induced nocifensive behaviors and spinal cord Fos protein expression. Intrathecal capsaicin-induced ablation of the central terminals of TRPV1 + neurons greatly reduced the behavioral responses and Fos elicited by low-dose (0.5%) formalin. In contrast, genetic ablation of the MrgprD-expressing subset of non-peptidergic unmyelinated afferents, which constitute a largely nonoverlapping population, altered neither the behavior nor the Fos induced by low-dose formalin. Remarkably, nocifensive behavior following high-dose (2%) formalin was unchanged in mice lacking either afferent population, or even in mice lacking both populations, which together make up the great majority of C-fiber nociceptors. Thus, at high doses, which are routinely used in the formalin test, formalin-induced ''pain" behavior persists in the absence of the vast majority of C-fiber nociceptors, which points to a contribution of a large spectrum of afferents secondary to non-specific formalin-induced tissue and nerve damage. Ó
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Introduction
The formalin test is a widely used model of persistent pain, and is a mainstay for the development of novel agents for the treatment of postoperative pain. Despite the prevalence of the formalin test in pain research, information as to the mechanisms that underlie the nocifensive behaviors produced by formalin is remarkably limited. There is some consensus that phase I behaviors result from acute activation of nociceptors by formalin, while phase II behaviors are driven in part by the central sensitization of spinal cord circuits secondary to the barrage of input that occurs during phase I [5, 27] . Other studies, however, provided evidence for an important contribution of ongoing afferent firing during phase II [25, 26] . In fact, electrophysiological studies demonstrated that Ad-and C-fiber nociceptors exhibit sustained firing during both phases of the formalin test, and even that presumably non-nociceptive Ab fibers are activated during phase I [16, 21] . These results are of particular interest in light of recent studies that demonstrated that at low doses (60.5%), formalin interacts directly with the non-specific cation channel TRPA1 [15, 17] , which is expressed in a subset of the unmyelinated TRPV1-expressing nociceptors [[11,24] , however, see 13]. Whether TRPA1 mediates the behavioral effects produced by higher doses of formalin that are routine in formalin testing in rodents is not known.
Taken together with the electrophysiological reports, the TRPA1 observations suggest that distinct complements of primary sensory neurons (nociceptors and non-nociceptive afferents) are engaged by different doses of formalin. The relationship between formalin dose, fiber type engaged, and behavior, however, is unclear. In the present study we used selective ablation of molecularly defined populations of primary afferent sensory fibers [4, 8] to determine which fiber types come into play at different doses, and more importantly, which subsets are necessary or sufficient for generating the prototypical behavioral responses to formalin. Thus, in order to ablate selectively the central terminals of nociceptors that express the heat and capsaicin receptor, TRPV1, we performed intrathecal injections of capsaicin in wildtype C57Bl/6 mice [4] . To ablate the largely non-overlapping population of cutaneous Cfibers that expresses the G protein-coupled receptor MrgprD, we made systemic injections of diphtheria toxin in mutant mice engineered with the human diphtheria toxin receptor (DTR) inserted into the Mrgprd locus (MrgprD DTR mice) [4] .
We report that both the behavioral and cellular (Fos induction in the spinal cord) responses produced by injection of low-dose formalin are dependent on nociceptors that express the heat and capsaicin receptor, TRPV1, likely through activation of TRPA1. In contrast, injection of high-dose formalin evokes nocifensive behavior that persists in the absence of the great majority of C-fiber nociceptors, 
